The role of next‑generation sequencing in hematologic malignancies
10.1007/s44313-024-00010-0
- Author:
Young‑Uk CHO
1
Author Information
1. Department of Laboratory Medicine, Asan Medical Center, University of Ulsan College of Medicine, 88, Olympic‑Ro 43‑Gil, Songpa‑Gu, Seoul 05505, Korea
- Publication Type:REVIEW
- From:Blood Research
2024;59():11-
- CountryRepublic of Korea
- Language:English
-
Abstract:
Next-generation sequencing (NGS) allows high-throughput detection of molecular changes in tumors. Over the past 15 years, NGS has rapidly evolved from a promising research tool to a core component of the clinical labo‑ ratory. Sequencing of tumor cells provides an important step in detecting somatic driver mutations that not only characterize the disease but also influence treatment decisions. For patients with hematologic malignancies, NGS has been used for accurate classification and diagnosis based on genetic alterations. The recently revised World Health Organization classification and the European LeukemiaNet recommendations for acute myeloid leukemia con‑ sider genetic abnormalities as a top priority for diagnosis, prognostication, monitoring of measurable residual disease, and treatment choice. This review aims to present the role and utility of various NGS approaches for the diagnosis, treatment, and follow-up of hemato-oncology patients.
